GILD vs NBIX
Gilead Sciences, Inc. and Neurocrine Biosciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | GILD | NBIX |
|---|---|---|
| Revenue | $29.4B | $2.9B |
| Net income | $8.5B | $478.6M |
| Gross margin | 78.8% | 98.2% |
| Net margin | 28.9% | 16.7% |
| Return on equity | 40.5% | 16.4% |
| Diluted EPS | $6.78 | $4.67 |
| Dividend / share | $3.16 | — |
| Payout ratio | 47.0% | — |
| Free cash flow | $9.5B | $748.7M |
| Equity | $22.7B | $3.3B |
| Net debt / equity | 0.77× | — |
| Current ratio | 1.55× | 3.39× |
| Revenue CAGR 5y | 3.6% | 22.3% |
| Profit CAGR 5y | 133.3% | 3.3% |
GILD bills 10.3× the revenue of NBIX, and keeps more of each dollar of revenue as profit (28.9% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | GILD | NBIX |
|---|---|---|
| FY2025 | $29.4B | $2.9B |
| FY2024 | $28.8B | $2.4B |
| FY2023 | $27.1B | $1.9B |
| FY2022 | $27.3B | $1.5B |
| FY2021 | $27.3B | $1.1B |
| FY2020 | $24.7B | $1.0B |
| FY2019 | $22.4B | $788.1M |
| FY2018 | $22.1B | $451.2M |
| FY2017 | $26.1B | $161.6M |
| FY2016 | $30.4B | $15.0M |
Net income by year
Bottom line
| Fiscal year | GILD | NBIX |
|---|---|---|
| FY2025 | $8.5B | $478.6M |
| FY2024 | $480.0M | $341.3M |
| FY2023 | $5.7B | $249.7M |
| FY2022 | $4.6B | $154.5M |
| FY2021 | $6.2B | $89.6M |
| FY2020 | $123.0M | $407.3M |
| FY2019 | $5.4B | $37.0M |
| FY2018 | $5.5B | $21.1M |
| FY2017 | $4.6B | $-142.5M |
| FY2016 | $13.5B | $-141.1M |
Advertisement
AdSense · Rectangle 336×280
More in this industry